Evaluating only Vir Biotechnology’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Market collapse.
Key Events Timeline
FOUNDING
Vir Biotechnology founded
LAYOFF
Market downturn forces cuts
SHUTDOWN
Mass Layoff Spiral: Vir Biotechnology ceases operations
Full Analysis
Free · no account needed
Documented cause
Vir Biotechnology raised $1.5B and partnered with GlaxoSmithKline to develop sotrovimab, a COVID-19 monoclonal antibody treatment. At peak, sotrovimab generated hundreds of millions in revenue as the US government stockpiled treatments. When COVID variants emerged that were resistant to sotrovimab, the FDA restricted its use in late 2021. Government stockpile demand evaporated. Vir cut 25% of staff in 2023 and another 38% in 2024, reducing from 800 employees to under 250 as it searched for new therapeutic programs.
Lesson
“COVID therapeutic companies built on a single pandemic-specific product face the most acute form of product-market fit risk: the market disappears by both variant evolution and pandemic resolution, simultaneously and unpredictably.”